Back to Agenda
China Town Hall
Session Chair(s)
Ling Su, PhD
Research Fellow
Yeehong Business School, China
In this forum, speakers from the National Medical Products Administration (NMPA) , academia and industry will present the progress in drug regulation, review China's biopharma innovation in the past decade, and discuss accelerating innovative drug approvals in China. Attendees will have an opportunity to discuss the issues related to drug development with NMPA officials, clinical researcher and industry executive.
Learning Objective : Describe the latest information on the National Medical Products Administration’s activities in drug regulation; Describe the trend in biopharma innovation in the past decade; Discuss the strategies for accelerating innovative drug development and approval in China.
Speaker(s)
Brief Introduction from the NMPA
Feng Zhu
China Center for Food and Drug International Exchange (CCFDIE), China
Director, Cooperation Department
The Progress of China's Drug Review and Approval Reform
Jianwu Zhang, PhD
National Medical Products Administration, China
Division Director, Drug Registration Department
Accelerating the Development and Approval of Innovative Drugs in China: Industry's Perspective
Wei Zhang
Boehringer Ingelheim, China
SVP, Head of Medicine, Greater China
The Past Decade of China's Biopharma Innovation
Xiaoyuan Chen, MD
Tsinghua University, China
Professor
Building a World-Class Hub for Biomedical Innovation - Case Study of Suzhou Industrial Park (SIP)
Gina Zhang
Division Head of Suzhou Industrial Park Investment Promotion Board, China
Have an account?